For Immediate Release
Chicago, IL – June 07, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Gilead (NASDAQ: GILD – Free Report ), BP (LON:BP) (NYSE: BP – Free Report ), Dow Chemical (NYSE: DOW – Free Report ), America Movil (NYSE: AMX – Free Report ) and MetLife (NYSE:MET) (NYSE: MET – Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for Wednesday: GILD, BP, DOW & More
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Gilead (NASDAQ: GILD – Free Report ), BP (NYSE:BP – Free Report ), and Dow Chemical (NYSE: DOW – Free Report ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>>
Gilead shares have been laggards lately, on persistent fears about drug pricing and other regulatory issues that haven't eased up even after the November election. The stock has lost -25.2% of its value over the last year vs. the -9.6% decline for the Zacks Biotech industry. Gilead’s HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens which now represent 42% of total Gilead HIV prescription volume. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales as the company saw a significant uptick in PrEP usage in 2017. However, Gilead will lose exclusivity for Viread this year in some countries outside the U.S., which should impact sales. Additionally, the HCV franchise continues to be undercompetitive and pricing pressure is leading to a massive decline in Harvoni and Sovaldi sales. (You can read the full research report on Gilead here >>> ).
BP share have gained +9.1% over the past 12 months, outperforming the Zacks Oil & Gas-International Integrated industry which has lost -0.8% over the same period, as well as rival Royal Dutch Shell (LON:RDSa) (up +5.1%). The Zacks analyst stresses that the petroleum giant’s upstream projects are expected to generte significant cash flows starting 2020 and beyond. Moreover, the company’s drilling operations are becoming efficient as reflected by the steady decline in non-productive time since 2012. However, the oil spill incident of 2010 in the BP-operated Macondo Prospect continues to affect the company. Although BP has cleared substantial litigation expenses related to the spill, it had to divest some of its best operating properties. The analyst sees the company's dividend to generally safe, but the high yield (currently yielding 6.6%) indicates some market nervousness. (You can read the full research report on BP here >>> ).
Dow Chemical shares have gained +11.1% over the past six months, outperforming the Zacks Chemicals Diversified industry (up +7.5% over the same period). The Zacks analyst likes the planned merger with DuPont (NYSE:DD), which is expected to create significant synergies. Dow should also gain from cost synergies associated with Dow Corning Silicones business and its strategic investments in the U.S. Gulf Coast and the Middle East. However, Dow’s agriculture business remains affected by depressed crop commodity prices. The company also faces pricing headwinds, feedstock cost pressure as well as weak demand in the energy market. (You can read the full research report on Dow Chemical here >>> ).
Other noteworthy reports we are featuring today include America Movil (NYSE:AMX – Free Report ) and MetLife (NYSE:MET – Free Report ).
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on GILD - FREE
Get the full Report on BP - FREE
Get the full Report on DOW - FREE
Get the full Report on AMX - FREE
Get the full Report on MET - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook (NASDAQ:FB): https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Gilead Sciences, Inc. (NASDAQ:GILD): Free Stock Analysis Report
BP p.l.c. (BP): Free Stock Analysis Report
Dow Chemical Company (The) (NYSE:DOW): Free Stock Analysis Report
America Movil, S.A.B. de C.V. (AMX): Free Stock Analysis Report
MetLife, Inc. (MET): Free Stock Analysis Report
Original post
Zacks Investment Research